69.45
-1.25 (-1.77%)
| Penutupan Terdahulu | 70.70 |
| Buka | 70.95 |
| Jumlah Dagangan | 851,776 |
| Purata Dagangan (3B) | 1,569,559 |
| Modal Pasaran | 5,576,022,528 |
| Harga / Pendapatan (P/E TTM) | 8.08 |
| Harga / Pendapatan (P/E Ke hadapan) | 55.25 |
| Harga / Jualan (P/S) | 3.42 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 19 Feb 2026 |
| Margin Keuntungan | 33.56% |
| Margin Operasi (TTM) | 82.43% |
| EPS Cair (TTM) | 6.39 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 459.70% |
| Nisbah Semasa (MRQ) | 3.89 |
| Aliran Tunai Operasi (OCF TTM) | 691.65 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 526.00 M |
| Pulangan Atas Aset (ROA TTM) | 24.42% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | PTC Therapeutics, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | -3.0 |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | -5.0 |
| Purata | -0.20 |
|
PTC Therapeutics Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when an RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 2.40% |
| % Dimiliki oleh Institusi | 101.06% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 119.00 (Barclays, 71.35%) | Beli |
| Median | 92.00 (32.47%) | |
| Rendah | 82.00 (RBC Capital, 18.07%) | Pegang |
| Purata | 94.40 (35.93%) | |
| Jumlah | 4 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 71.62 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Morgan Stanley | 23 Feb 2026 | 92.00 (32.47%) | Beli | 70.50 |
| B of A Securities | 20 Feb 2026 | 93.00 (33.91%) | Beli | 70.66 |
| RBC Capital | 20 Feb 2026 | 82.00 (18.07%) | Pegang | 70.66 |
| Wells Fargo | 20 Feb 2026 | 86.00 (23.83%) | Beli | 70.66 |
| Barclays | 28 Jan 2026 | 119.00 (71.35%) | Beli | 75.60 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 05 Feb 2026 | Pengumuman | PTC Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, Feb. 19, 2026 |
| 12 Jan 2026 | Pengumuman | PTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference |
| 08 Jan 2026 | Pengumuman | PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |